TCL Archive Britain’s Cancer Czar Begins Examination of Risks and Benefits of Mammography October 28, 2011
TCL Archive RAS Mutations Can Predict Resistance To Vectibix, FOLFOX Combination Treatment September 27, 2013
TCL Archive Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge? October 7, 2005
